Excited to highlight our newest study: JCI Insight - Semaglutide-induced loss of skeletal muscle mass is blunted by co-administration of ketone esters https://t.co/A5WxHpPHRP
@UAlberta_FoMD
Planning to start semaglutide (Ozempic/Wegovy) in the near future? Or, have you started the medication within the past two weeks?
If so, you are invited to participate in the GLIMMER research study. We are interested to learn about how semaglutide affects your heart and muscle mass. Our goal is to improve care for patients who use this medication.
This study involves 3 in-person visits to Mazankowski Alberta Heart Institute. Each visit will take about 3 hours. To learn more and to find out if you’re eligible, please visit: https://t.co/oawIYBDZ6M
If you have any questions, please contact the GLIMMER study team at [email protected] or call 780-492-9010.
Advances in Ozempic research: weight loss without muscle loss!
Some potentially game-changing news from the @DyckLab today… our new study in mice shows that drinking ketone esters while taking Ozempic prevents the loss of cardiac and skeletal muscle without impacting fat loss.
With so much attention on ketones helping the failing heart, let's not forget about the other organ systems affected in heart failure. We've reviewed, and encourage exploring, the non-cardiac effects of ketones on exercise intolerance in HF @JasonRBDyck https://t.co/S3McPaqkQW
Our latest publication with an outstanding team in the Netherlands.
Potential Benefits of Ketone Therapy as a Novel Immunometabolic Treatment for Schizophrenia
@DyckLab
https://t.co/9uaWpuz8CV
🧵 3/3
Given the growing number of people taking this drug who have no cardiovascular disease or who are not classified as obese, “we suggest that cardiac structure and function be carefully evaluated in previous and ongoing clinical studies.”
🧵1/3
Our study may require some context:
We started this work to establish a mouse model that we could use to study why some clinical trials using #Ozempic reported loss of skeletal muscle mass.
Using mice, we found that heart muscle is also decreased with Ozempic
We are excited to share our latest paper:
Semaglutide Reduces Cardiomyocyte Size and Cardiac Mass in Lean and Obese Mice | JACC: Basic to Translational Science https://t.co/5qlNlPqZpf
🧵2/3
The decrease in heart size induced by Ozempic occurred in both obese and lean mice.
This leaves us with a number of questions- 1) does this also occur in humans? 2) is the detrimental? 3) is this reversible? 4) can this cause later onset cardiac issues?
We are excited to share our latest paper:
Semaglutide Reduces Cardiomyocyte Size and Cardiac Mass in Lean and Obese Mice | JACC: Basic to Translational Science https://t.co/5qlNlPqZpf
Huge congratulations also goes out to our postdoc @MattDMartens for being awarded a @CIHR_IRSC Postdoctoral Fellowship!!
🎉 Congrats Matt on this fantastic achievement 🎉
Mya also earned a Medical Sciences Graduate Program Scholarship from @UAlberta_FoMD, a Walter Johns Graduate Fellowship from @UAlberta and a Grant for Women Graduate Students from @soroptimist!
Congratulations Mya! 🎉
We're welcoming undergraduate student Darius Sahid to the lab this summer!
Darius was funded by a summer studentship from the @UAlberta Undergraduate Research Initiative 🎊
Congratulations goes to @DaniaAlRimawi who successfully defended her undergraduate honours thesis last month!
We're proud to share that Dania was ⭐️awarded⭐️summer studentships from @NSERC_CRSNG, @WCHRIUofA and @ABInnovates to keep her research going this summer!
We're excited to share that PhD candidate and all around ketone expert, @Shubham_Soni26, successfully defended his PhD Thesis this week!
Congrats Dr. Soni! We cannot wait to see what you accomplish as a clinician scientist!